Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth

Clinical Cancer Research

Volumn 13, Issue 8, 2007, Pages 2429-2440

  Carrillo, Jaime ^a   García Aragoncillo, Eva ^a   Azorín, Daniel ^b   Agra, Noelia ^a   Sastre, Ana ^c   González Mediero, Imelda ^b   García Miguel, Purificación ^c   Pestaña, Ángel ^a   Gallego, Soledad ^d   Segura, Dolores ^e   Alonso, Javier ^a,f  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^c HOSPITAL INFANTIL LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; DOXYCYCLINE; JANUS KINASE 1; ONCOPROTEIN; PONASTERONE A; RNA BINDING PROTEIN EWS;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EWING SARCOMA; GENE OVEREXPRESSION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NEUROBLASTOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; RNA INTERFERENCE; WESTERN BLOTTING;

BONE NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CHOLECYSTOKININ; CLONING, MOLECULAR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH SUBSTANCES; HELA CELLS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; SARCOMA, EWING'S;

EID: 34247877772     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1762     Document Type: Article

References (48)

1. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol 2003;40: 276-87.
2. Kovar H. Ewing's sarcoma and peripheral primitive neuroectodermal tumors after their genetic union. Curr Opin Oncol 1998;10:334-42.
3. Janknecht R. EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 2005;363:1-14.
4. Kovar H. Context matters: the hen or egg problem in Ewing's sarcoma. Semin Cancer Biol 2005;15: 189-96.
5. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359:162-5.
6. May WA, Lessnick SL, Braun BS, et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993;13: 7393-8.
7. Arvand A, Welford SM, Teitell MA, Denny CT. The COOH-terminal domain of FLI-1 is necessary for full tumorigenesis and transcriptional modulation by EWS/FLI-1. Cancer Res 2001;61:5311-7.
8. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997;99:239-47.
9. Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 1995;11:1049-54.
10. Prieur A, Tirade F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24:7275-83.
11. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005;65:8984-92.
12. May WA, Gishizky ML, Lessnick SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 1993;90:5752-6.
13. Bailly RA, Bosselut R, Zucman J, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994; 14:3230-41.
14. Hahm KB, Cho K, Lee C, et al. Repression of the gene encoding the TGF-β type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 1999; 23:222-7.
15. Abaan OD, Levenson A, Khan O, Furth PA, Uren A, Toretsky JA. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's sarcoma tumorigenesis. Oncogene 2005;24:2715-22.
16. Dauphinot L, De Oliveira C, Melot T, et al. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression. Oncogene 2001;20:3258-65.
17. Zwerner JP, May WA. Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines. Oncogene 2002;21:3847-54.
18. Rozengurt E, Walsh JH. Gastrin, CCK, signaling, and cancer. Annu Rev Physiol 2001;63:49-76.
19. Mendiola M, Carrillo J, Garcia E, et al. The orphan nuclear receptor DAX1 is up-regulated by the EWS/ FLI1 oncoprotein and is highly expressed in Ewing tumors. Int J Cancer 2006;118:1381-9.
20. van Valen F, Winkelmann W, Jurgens H. Expression of functional Y1 receptors for neuropeptide Y in human Ewing's sarcoma cell lines. J Cancer Res Clin Oncol 1992;118:529-36.
21. Hubert RS, Vivanco I, Chen E, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 1999;96:14523-8.
22. Khan J, Wei JS, Ringner M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001;7:673-9.
23. Schaefer KL, Brachwitz K, Wai DH, et al. Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3. Cancer Res 2004;64:3395-405.
24. Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res 2005;65:4633-44.
25. Baer C, Nees M, Breit S, et al. Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcoma. Int J Cancer 2004;110:687-94.
26. Staege MS, Hutter C, Neumann I, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 2004;64:8213-21.
27. Fukuma M, Okita H, Hata J, Umezawa A. Up-regulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma. Oncogene 2003;22:1-9.
28. Nishimori H, Sasaki Y, Yoshida K, et al. The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors. Oncogene 2002;21:8302-9.
29. Friedman JM, Vitale M, Maimon J, Israel MA, Horowitz ME, Schneider BS. Expression of the cholecystokinin gene in pediatric tumors. Proc Natl Acad Sci U S A 1992;89:5819-23.
30. Watanabe G, Nishimori H, Irifune H, et al. Induction of tenascin-C by tumor-specific EWS-ETS fusion genes. Genes Chromosomes Cancer 2003;36:224-32.
31. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat Genet 1997;17: 495-7.
32. Nakatani F, Tanaka K, Sakimura R, et al. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 2003;278:15105-15.
33. Zwerner JP, Guimbellot J, May WA. EWS/FLI function varies in different cellular backgrounds. Exp Cell Res 2003;290:414-9.
34. Todisco A, Takeuchi Y, Urumov A, Yamada J, Stepan VM, Yamada T. Molecular mechanisms for the growth factor action of gastrin. Am J Physiol 1997;273:G891-8.
35. Singh P, Owlia A, Espeijo R, Dai B. Novel gastrin receptors mediate mitogenic effects of gastrin and processing intermediates of gastrin on Swiss 3T3 fibroblasts. Absence of detectable cholecystokinin (CCK) -A and CCK-B receptors. J Biol Chem 1995;270:8429-38.
36. Cheng ZJ, Harikumar KG, Holicky EL, Miller LJ. Heterodimerization of type A and B cholecystokinin receptors enhance signaling and promote cell growth. J Biol Chem 2003;278:52972-9.
37. Wank SA. G protein-coupled receptors in gastrointestinal physiology. I. CCK receptors: an exemplary family. Am J Physiol 1998;274:G607-13.
38. Rorie CJ, Thomas VD, Chen P, Pierce HH, O'Bryan JP, Weissman BE. The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res 2004;64:1266-77.
39. Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res 2006; 4:851-9.
40. Vogel BE, Hedgecock EM. Hemicentin, a conserved extracellular member of the immunoglobulin superfamily, organizes epithelial and other cell attachments into oriented line-shaped junctions. Development 2001;128:883-94.
41. Schneider BS, Helson L, Monahan JW, Friedman JM. Expression of the cholecystokinin gene by cultured human primitive neuroepithelioma cell lines. J Clin Endocrinol Metab 1989;69:411-9.
42. Reubi JC, Koefoed P, Hansen TO, et al. Procholecystokinin as marker of human Ewing sarcomas. Clin Cancer Res 2004;10:5523-30.
43. Paddison PJ, Hannon GJ. RNA interference: the new somatic cell genetics? Cancer Cell 2002;2: 17-23.
44. Yee D, Favoni RE, Lebovic GS, et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest 1990;86:1806-14.
45. Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56:4570-4.
46. Uren A, Merchant MS, Sun CJ, et al. β-Platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene 2003;22:2334-42.
47. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005;65:3868-76.
48. Benini S, Manara MC, Baldini N, et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 2001;7: 1790-7.